<DOC>
	<DOCNO>NCT00443911</DOCNO>
	<brief_summary>Age-related macular degeneration one major cause blindness western world . There exsudative non-exsudative form age-related macular degeneration.Most study concentrate exsudative form . In non-exsudative form policy generally watch see , patient risk develop exsudative form . So far , accept therapy reach stable disease non-exsudative form high-dose supplementation antioxidant . Another approach improve visual acuity patient non-exsudative form macular degeneration rheohemapheresis treatment , extracorporeal therapy plasma separate blood cell . By use hollow fiber filter plasma deplete high molecular weight protein reinfused . Others report describe supplementation lutein ( vitamin A derivative ) possible treatment option . However , none study yet examine combination rheohemapheresis lutein supplementation .</brief_summary>
	<brief_title>Rheohemapheresis Lutein Supplementation Non-Exsudative Form Age-Related Macular Degeneration</brief_title>
	<detailed_description>Rheohemapheresis perform 5 cycle . One cycle consist 2 rheohemapheresis treatment day 1 day 4 . A cycle last 4 week repeat every fourth week . During treatment &gt; 75 % 100 % patient total plasma volume filtered.General medical review , ETDRS Radner visual acuity assessment , ophthalmologic examination , ocular image OCT 3 , autofluorescein image infrared imaging , multifocal ERG , ocular echography , blood examination perform .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Study eye nonexsudative AMD AREDS II III &gt; 10 large soft , / confluent drusen within 3000 nm foveal centre best correct visual acuity 0.06 1.0 use ETDRS chart ( letter score 3 50 letter ) / without geographic atrophy le 3 disc diameter within 3000 nm foveal centre Â´ . / without serous pigment epithelial detachment without clearly identifiable neovascularisation Patients must elevate baseline concentration least one rheologic parameter ( serum cholesterol level &gt; 200 mg/dL , fibrinogen level &gt; 390 mg/dL , plasmaviscosity &gt; 1.6 mPa*s ) Men woman age 50 99 year . Study eye exsudative AMD Study eye concomitant retinal choroidal disorder AMD Study eye significant central lens opacity / condition limit view fundus poor general condition hematocrit &lt; 30 % coagulation disorder ( incl . marcoumar therapy ) significant cardiac problem ( &gt; NYHA II ) history ( &lt; 12 month ) cardiac infarction uncontrolled arterial hypertension recent history ( &lt; 3 month ) cerebral vascular infarction cerebrovascular disease IV uncontrolled diabetes insufficient antecubital venous access lutein supplementation within last 3 month weight &lt; 45 kg hematooncological disorder Patients unwilling adhere visit examination schedule</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>age-related macular degeneration , rheopheresis , lutein</keyword>
</DOC>